My watch list  


Systematic (IUPAC) name
CAS number 138112-76-2
ATC code N06AX22
PubChem 82148
Chemical data
Formula C15H17NO2 
Mol. mass 243.301
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life 1 to 2 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes  ?

Agomelatine (Valdoxan®, Melitor®) is chemical compound that is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression (forced swimming test in rodents). It is concluded that the antidepressant-like activity in this model most probably involves a combination of both its melatonin agonist and 5-HT(2C) receptor antagonist properties.

Controlled studies with humans have shown that agomelatine is comparable to paroxetine in treatment of major depression. Agomelatine showed significant benefits over paroxetine due to the complete absence of side effects including the associated sexual side effects that are troublesome with some antidepressants. Because of its actions upon the melatonin receptors, agomelatine shows a marked improvement in sleep quality. However unlike other antidepressants with sedative effects there were no associated instances of daytime drowsiness.

On 27 July 2006 the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMEA) recommended a refusal of the marketing authorisation of Valdoxan/Thymanax. The major concern was that efficacy had not been sufficiently shown. The CHMP had no special concerns about the side effects.

According to the pipeline page on, the company plans to file agomelatine (AGO178) in 2008. [1]


  1. ^ Products in Development
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Agomelatine". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE